Cambrex has completed a $38 million capacity expansion at its small molecule active pharmaceutical ingredient (API) manufacturing facility in High Point, North Carolina.
This expansion doubles the facility’s manufacturing capacity, with new analytical and chemical development laboratories, two new clinical manufacturing suites, and a small-scale commercial manufacturing operation with three work centres and 2,000 litres
“When we began this project in 2021, our vision extended far beyond capacity,” said Tom Loewald, CEO, Cambrex. “We designed a facility that can continue to deliver on client needs as the industry evolves, with state-of-the-art technology and laboratory equipment, an energy-efficient infrastructure, and clinical to commercial manufacturing scale.”
The High Point capabilities complement those of previously acquired Snapdragon Chemistry, which specialises in R&D for API batch and continuous flow process development. The combination of Snapdragon Chemistry and the expansion in High Point allows clients to utilise one vendor for flow chemistry scale-up from R&D through commercialisation.
In addition to the new infrastructure, more than 70 new jobs have been created as Cambrex continues to recruit expert pharmaceutical R&D scientists and staff to the region.
Dan Bowles, Vice President and General Manager, Cambrex High Point, said: “We are extremely excited about this expansion in North Carolina, which would not have been possible without the support of the State’s leadership and economic development programs, and their focus on nurturing the region’s skilled and diverse workforce.”
Cambrex continues to expand its capabilities and capacity across its North American and European network to meet the growing demand for outsourced product development and manufacturing services.
